23andMe has taken off as an industry leader in the emerging consumer genetics space. Below, we explore the company's strategy and where it may be headed next.
Direct-to-consumer (D2C) DNA testing kits are making a splash.
Many are jumping on the opportunity to better understand their health, using at-home genetic testing to assess everything from food sensitivities to risk of disease.
And companies are looking to capitalize on the market — estimated to bypass $310M by 2022 — including leading consumer genetics company 23andMe.
